Fig. 1.
OS of patients according to cytogenetic and biological characteristics.
(A) Normal karyotypes versus abnormal karyotypes. (B) Hyperdiploid karyotypes versus hypodiploid karyotypes. (C) Conventional chemotherapy: hyperdiploid patients versus hypodiploid patients. (D) HDC SCT: hyperdiploid patients versus hypodiploid patients. (E) Absence or presence of chromosome 13 loss or deletion. (F) Impact of chromosome number pattern in patients with chromosome 13q abnormality. (G) Impact of chromosome number pattern in patients with both a high β2-microglobulin level and chromosome 13q abnormality. (H) Stratification of patients according to the absence or presence of a hypodiploid karyotype and high β2-microglobulin.
